This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy International Europe

Savings Deadline Expires In:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
2-4 December 2024
Convention Centre DublinDublin, Ireland

Dr Sven Kili, MD
Partner at Saisei Ventures
Speaker

Profile

Dr. Sven Kili is a respected KOL in healthcare and biotechnology, boasting over 20 years ofexperience. He began as a surgeon in the NHS, where he gained valuable insights into patientcare. Transitioning to Cell and Gene Therapies (CGT), Sven played key roles in getting key CGTproducts approved and into the market. With expertise across all stages of CGT development,he has led teams in both big companies and startups.

Sven is a partner at Saisei Ventures, a boutique therapeutic investment firm focussed ongrowing Japanese technologies. He also heads his consulting firm, Sven Kili Consulting, oNeringstrategic guidance to organizations in the biotech and healthcare sectors while also serving asthe Chief Development ONicer for CCRM (Centre for Commercialization of RegenerativeMedicine) and OmniaBio.

Sven actively contributes to industry boards and committees, including the BIA CGTAC,Innovation Hubs for Gene Therapy, ISCT, and ARM. Sven holds a visiting chair at UCL, where heheads the steering committee for a post-grad degree in Cell & Gene Therapy manufacturing andcommercialisation. His dedication to advancing regenerative medicine and CGT is reflected inhis multifaceted roles and ongoing eNorts to shape the future of healthcare through innovationand strategic collaboration.

Agenda Sessions

  • Fuelling Funding: Securing the Future Innovation and Development of Advanced Therapies

    16:15